Certain progestins prevent the enhancing effect of 17β-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 4, 2009, Pages 586-593

  Zerr Fouineau, Murielle ^a   Jourdain, Marie ^a   Boesch, Caroline ^a   Hecker, Markus ^b   Bronner, Christian ^a   Schini Kerth, Valérie B ^a,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CNRS   (France)

Author keywords

17 estradiol; Endothelial nitric oxide synthase; GTP cyclohydrolase; Progestins; Thrombosis

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; GLUCOCORTICOID RECEPTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NITRIC OXIDE; NOMEGESTROL ACETATE; PROGESTERONE; SEPIAPTERIN; HORMONE ANTAGONIST; MEGESTROL; MESSENGER RNA; NOS3 PROTEIN, HUMAN; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; PTERIN DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; CELL CULTURE; DOSE RESPONSE; ENZYMOLOGY; METABOLISM; THROMBOCYTE; THROMBOSIS; TIME;

BLOOD PLATELETS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ESTRADIOL; GTP CYCLOHYDROLASE; HORMONE ANTAGONISTS; HUMANS; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL; MIFEPRISTONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NORPREGNADIENES; PLATELET AGGREGATION; PROGESTERONE; PROGESTERONE CONGENERS; PTERINS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; RNA, MESSENGER; THROMBOSIS; TIME FACTORS;

EID: 63449138493     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.178004     Document Type: Article

References (53)

1. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273:199-208.
2. Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, Liao JK, De Caterina R. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res. 2000;87:19-25.
3. Pervin S, Singh R, Rosenfeld ME, Navab M, Chaudhuri G, Nathan L. Estradiol suppresses MCP-1 expression In vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1575-1582.
4. Akishita M, Ouchi Y, Miyoshi H, Orimo A, Kozaki K, Eto M, Ishikawa M, Kim S, Toba K, Orimo H. Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis. 1996;125:27-38.
5. Wagner AH, Schroeter MR, Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J. 2001;15:2121-2130.
6. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:401-406.
7. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, and Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
8. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J Biol Chem. 2005;280:19704-19710.
9. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 1988;244:19-22.
10. Thompson LP, Pinkas G, Weiner CP. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation. 2000;102:445-451.
11. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 1995;360:291-293.
12. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, Shaul PW. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997;81:355-362.
13. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994;91:5212-5216.
14. Stirone C, Chu Y, Sunday L, Duckles SP, Krause DN. 17β-Estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. Eur J Pharmacol. 2003;478:35-38.
15. McNeill AM, Kim N, Duckles SP, Krause DN, Kontos HA. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke. 1999;30:2186-2190.
16. Okano H, Jayachandran M, Yoshikawa A, Miller VM. Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. J Cardiovasc Pharmacol. 2006;47:621-628.
17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
18. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J. 2007;21:265-273.
19. Klein-Soyer C, Beretz A, Millon-Collard R, Abecassis J, Cazenave JP. A simple in vitro model of mechanical injury of confluent cultured endothelial cells to study quantitatively the repair process. Thromb Haemost. 1986;56:232-235.
20. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7-S16.
21. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab. 2004;15:277-285.
22. Svensson LO, Johnson SH, Olsson SE. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil, Trisequence/Provera and Divina. A randomized, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas. 1994;18:229-238.
23. Hamada AL, Maruo T, Samoto T, Yoshida S, Nash H, Spitz IM, Johansson E. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecol Endocrinol. 2003;17:247-254.
24. Vanin AF. Iron diethyldithiocarbamate as spin trap for nitric oxide detection. Methods Enzymol. 1999;301:269-279.
25. Kleschyov AL, Munzel T. Advanced spin trapping of vascular nitric oxide using colloid iron diethyldithiocarbamate. Methods Enzymol. 2002;359:42-51.
26. Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, Gachet C. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol. 2004;272:13-28.
27. Kleinert H, Wallerath T, Euchenhofer C, et al. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension. 1998;31:582-588.
28. Sumi D, Hayashi T, Jayachandran M, Iguchi A. Estrogen prevents destabilization of endothelial nitric oxide synthase mRNA induced by tumor necrosis factor alpha through estrogen receptor mediated system. Life Sci. 2001;69:1651-1660.
29. Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M. Glucocorticoid response elements and 11β-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res. In press.
30. Kook K, Gabelnick H, Duncan G. Pharmacokinetics of levonorgestrel 0.75 mg tablets. Contraception. 2002;66:73-76.
31. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
32. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem. 2003;278:2118-2123.
33. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
34. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
35. McCabe TJ, Fulton D, Roman LJ, Sessa WC. Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation. J Biol Chem. 2000;275:6123-6128.
36. Schulz E, Anter E, Zou MH, Keaney JF Jr. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation. 2005;111:3473-3480.
37. Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem Biophys. 2004;41:415-434.
38. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593-615.
39. Serova LI, Maharjan S, Huang A, Sun D, Kaley G, Sabban EL. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res. 2004;1015:1-8.
40. Lam KK, Lee YM, Hsiao G, Chen SY, Yen MH. Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause. 2006;13:294-302.
41. Serova LI, Filipenko M, Schilt N, Veerasirikul M, Sabban EL. Estrogen-triggered activation of GTP cyclohydrolase 1 gene expression: role of estrogen receptor subtypes and interaction with cyclic AMP. Neuroscience. 2006;140:1253-1263.
42. Mitchell BM, Dorrance AM, Mack EA, Webb RC. Glucocorticoids decrease GTP cyclohydrolase and tetrahydrobiopterin-dependent vasorelaxation through glucocorticoid receptors. J Cardiovasc Pharmacol. 2004;43:8-13.
43. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96:13357-13362.
44. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol. 1987;90:687-692.
45. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol. 1986;88:411-415.
46. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148:1482-1489.
47. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992;85:2284-2290.
48. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100:350-356.
49. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A. 1988;85:2800-2804.
50. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation. 2000;101:2144-2148.
51. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001;104:2826-2831.
52. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000;321:1190-1195.
53. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-1588.